🇺🇸 FDA
Pipeline program

SOTATERCEPT, SOTATERCEPT, sotatercept, sotatercept

MK-7962-038

Phase 3 small_molecule active

Quick answer

SOTATERCEPT, SOTATERCEPT, sotatercept, sotatercept for ​​Pulmonary Arterial Hypertension (PAH) is a Phase 3 program (small_molecule) at Merck Sharp and Dohme with 1 ClinicalTrials.gov record(s).

Program details

Company
Merck Sharp and Dohme
Indication
​​Pulmonary Arterial Hypertension (PAH)
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials